Tatva Chintan Pharma Chem reports strong profit growth in Q2

Tatva Chintan Pharma Chem Limited has reported a robust financial performance for the quarter and half-year ended September 30, 2025. For the quarter, the company's total comprehensive income surged to INR 136.01 million compared to INR 106.33 million in the preceding quarter. Profit after tax also saw a substantial rise to INR 99.17 million from INR 66.86 million in the previous quarter, with a basic earnings per share (EPS) of INR 4.39.

Looking at the half-year figures, total comprehensive income reached INR 242.34 million, up from INR 182.44 million in the corresponding previous half-year. Profit after tax for the six-month period stood at INR 166.03 million, an increase from INR 127.86 million in the prior year's comparable period, with half-yearly basic EPS reported at INR 7.35.

The company's revenue from operations for the quarter ended September 30, 2025, was INR 300.95 million, slightly higher than the INR 288.66 million recorded in the previous quarter. For the half-year, revenue from operations reached INR 589.61 million, an improvement from INR 579.52 million in the previous half-year.